Results 261 to 270 of about 9,958,775 (335)

CEACAM5-Targeted Therapies in Solid Tumors: Biological Barriers and Next-Generation Precision Strategies. [PDF]

Drug Des Devel Ther
Ye T, Mei R, Liu X, Huang P.
europepmc   +1 more source

Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion. [PDF]

MAbs
Thomas J, Xu G, Lock H, Song Q, Yin Y, Luo W, Hong K, Lou L, Wang C, Chinn L, Mozaffarian N, Dudani J, Bessette P, Zhou C, Lan R, Chen B, Mehta N.   +16 more
europepmc   +1 more source

Immune Cell Engagers and "Masking Immunotherapy" for Solid Tumors: Focus on Head and Neck Cancers. [PDF]

Cancers (Basel)
Nardo G, Lenoci D, Lucchetta M, Licitra L, De Cecco L, Cavalieri S.   +5 more
europepmc   +1 more source

Targeting tumor-selective membrane-associated PCNA enables selective antibody-drug conjugate therapy. [PDF]

Oncoimmunology
Abu Ahmad M, Ungar-Malma NM, Naumchik A, Machluf-Katz N, Radinsky O, Adi Eisdorfer S, Gara A, Istoyler Y, Alon I, Sevilla-Sanchez D, Campbell KS, Kaufman B, Elkabets M, Porgador A.   +13 more
europepmc   +1 more source

DNAM-1-Stimulated NK-92 Cells Exert Preferential Cytotoxic and Apoptosis-Associated Effects on Hormone-Independent Solid Tumor Cell Lines. [PDF]

Int J Mol Sci
Dastouri M, Elmusa F.
europepmc   +1 more source